CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Cumulative Genocea Biosciences Inc 's Total Debt to Equity for Trailing Twelve Months Period

GNCA's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

GNCA Total Debt to Equity for Trailing Twelve Months Period

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity Growth 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Total Debt Growth -20.75 % -36.61 % -27.88 % -28.25 % -28.61 %
Total Debt to Equity for Trailing Twelve Months Period 0.44 0.54 0.82 1.34 1.31
Total Ranking # 1972 # 2205 # 2315 # 2808 # 2935
Seq. Equity Growth -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Total Debt Growth -12.97 % -11.34 % 1.37 % 1.33 % -30.39 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2022
On the trailing twelve months basis Due to repayements of liabilities of -12.97% Genocea Biosciences Inc decreased Total Debt to Equity for Trailing Twelve Months Period in the I. Quarter to 0.44, below company's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 59 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Genocea Biosciences Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
GNCA Charts and Quotes
Total Debt to Equity GNCA in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 60
Sector # 442
S&P 500 # 2334


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
2.24 0.98 0.01
(Jun 30 2018)   (Dec 31 2016)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Total Debt to Equity for Trailing Twelve Months Period
Nanostring Technologies Inc   1.16 
Acorda Therapeutics Inc   1.14 
Avalon Globocare Corp   1.00 
Novavax inc  0.86 
Adma Biologics Inc   0.85 
Greenlight Biosciences Holdings Pbc  0.81 
Genocea Biosciences Inc   0.79 
Sorrento Therapeutics Inc   0.71 
Biogen Inc   0.66 
Axcella Health Inc   0.62 
Qiagen N v   0.60 
Erytech Pharma S a   0.58 
Outlook Therapeutics Inc   0.58 
Eloxx Pharmaceuticals Inc   0.57 
Allena Pharmaceuticals Inc.  0.52 
Xtant Medical Holdings Inc   0.50 
Kaleido Biosciences Inc   0.48 
Codiak Biosciences Inc   0.46 
Oyster Point Pharma Inc   0.38 
Valneva Se  0.36 
Rubius Therapeutics Inc   0.35 
Pluri Inc   0.34 
Cidara Therapeutics Inc   0.33 
Cannabis Global Inc.  0.32 
Eiger Biopharmaceuticals Inc   0.31 
Zivo Bioscience Inc   0.27 
Neurocrine Biosciences Inc   0.26 
Candel Therapeutics Inc   0.26 
Applied Genetic Technologies Corporation  0.25 
Humacyte Inc   0.24 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com